BlackRock
DRMA icon

BlackRock’s Dermata Therapeutics DRMA Stock Holding History

BlackRock’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7
Closed -$22K – 5877
2022
Q1 		$22K Buy
7
+4
+133% +$13.7K ﹤0.01% 5554
2021
Q4 		$15K Buy
3
+1
+50% +$8.84K ﹤0.01% 5572
2021
Q3 		$26K Buy
+2
New +$23.7K ﹤0.01% 5368

Other funds holding DRMA

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCA
Sage Capital Advisors Sioux Falls, South Dakota $482M AUM 34.73% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock's DRMA Position: Q2 2022 in Review

BlackRock sold out of Dermata Therapeutics (DRMA) in Q2 2022, closing a stake of 7 shares — an estimated $22K sold.

BlackRock first reported a position in DRMA in Q3 2021 and held it in 3 quarters. The position peaked at $26K in Q3 2021. 10 funds tracked by Wall St. Rank hold DRMA as of Q2 2022.

  • BlackRock reported no remaining Dermata Therapeutics position as of Q2 2022 after selling out during the quarter.
  • BlackRock sold 7 Dermata Therapeutics shares in Q2 2022, an estimated $22K.
  • BlackRock first reported a position in Dermata Therapeutics in Q3 2021 and held it in 3 quarters.
  • BlackRock's Dermata Therapeutics position peaked at $26K in Q3 2021.
  • 10 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q2 2022.

Based on BlackRock's 13F filing for Q2 2022, filed 12 Aug 2022.